PNNL researchers are opening up a new front in the fight to stop viral pathogens, protecting people against multiple viruses.

Alex Beliaev, a biologist at PNNL, was named a Society for Industrial Microbiology and Biotechnology fellow.

Over the next four years, PNNL and University of Arizona will develop open-source computational tools to better identify and characterize the viruses associated with the human microbiome.

Scientists plumbed the depths of nearly 3,000 soil samples from around the globe to compile the heftiest atlas of soil viruses ever created.

A cross-institutional team of scientists developed PeakQC, a new software tool for automated quality control of mass spectrometry data.

Three PNNL researchers will receive five continuous years of funding for projects through highly competitive DOE Early Career Research Program awards.

Despite the widespread presence of RNA viruses in soils, little is known about the relative contributions and interactions of biological and environmental factors shaping the composition of soil RNA viral communities.

Ljiljana Paša-Tolić, a PNNL fellow, is the recipient of the 2024 International Mass Spectrometry Foundation’s Jochen Franzen Award. 

New research sheds light on the biomolecular dangers of night shift work.

Vigorous exercise burns fat more in males than in females, but the benefits of exercise are broad for both sexes.

PNNL contributes to a nationwide research consortium investigating the molecular mechanisms triggered by endurance training.

Data reveals mechanisms in our bodies that can help us fight viral pathogenesis.

Scientists have learned more about how to protect the insulin-producing cells that die in patients with Type 1 diabetes.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

The new PTM-Psi workflow opens the door for uncovering molecular insights within proteomics datasets.

Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.

PNNL scientists publish paper and host workshops to share threat-agnostic vision for biodefense.